Express News | CorMedix Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
CorMedix Shares Rise 6% After DefenCath Meets Payment Criteria
By Chris Wack CorMedix shares were up 6% to $5.73 after the company said that the Center for Medicare & Medicaid Services has determined that its DefenCath product meets the criteria for a transition
CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD
CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD
CorMedix: TDAPA Program Provides for Five Years Additional Payment Reimbursement >CRMD
CorMedix: TDAPA Program Provides for Five Years Additional Payment Reimbursement >CRMD
Express News | CorMedix Inc. Announces CMS Grants Transitional Drug Add-On Payment To DefenCath
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
CVAC, SBNY and CRMD Are Among After Hour Movers
Express News | CorMedix Announces U.S. Inpatient Commercial Availability Of DefenCath
Express News | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of Defencath® (Taurolidine and Heparin)
12 Health Care Stocks Moving In Friday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. The company's market cap stands at $40.7 million. Allarity Therapeutics (NASDAQ:ALLR
Two Of CorMedix Abstracts Accepted For Presentation At SHEA Conference
Two Of CorMedix Abstracts Accepted For Presentation At SHEA Conference
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today
When Will CorMedix Inc. (NASDAQ:CRMD) Become Profitable?
CorMedix Inc. (NASDAQ:CRMD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. CorMedix Inc., a biopharmaceutical company, focuses on de
Truist Financial Remains a Buy on Cormedix (CRMD)
CorMedix Price Target Maintained With a $10.00/Share by Needham
CorMedix Price Target Maintained With a $10.00/Share by Needham
Express News | Needham Reiterates Buy on Cormedix, Maintains $10 Price Target
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down about 0.2% The iShares Biotechnology ETF (IBB) rose 0.
CorMedix to Supply to DefenCath to Florida-based Dialysis Organization
CorMedix (CRMD) said Monday it entered a five-year agreement to supply its DefenCath product to Florida-based dialysis organization ARC Dialysis. DefenCath was approved in the US in November 2023 and
No Data